These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33755163)

  • 21. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.
    Psaty BM; Weiss NS; Furberg CD; Koepsell TD; Siscovick DS; Rosendaal FR; Smith NL; Heckbert SR; Kaplan RC; Lin D; Fleming TR; Wagner EH
    JAMA; 1999 Aug; 282(8):786-90. PubMed ID: 10463718
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation.
    Puthumana J; Wallach JD; Ross JS
    JAMA; 2018 Jul; 320(3):301-303. PubMed ID: 30027239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
    Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
    Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. American Heart Association--Scientific Sessions 2008--Studies with investigative drugs--Part 2.
    Kirkham K
    IDrugs; 2009 Jan; 12(1):7-9. PubMed ID: 19127495
    [No Abstract]   [Full Text] [Related]  

  • 25. American Heart Association--Scientific Sessions 2008--Studies with investigative drugs--Part 1.
    Kirkham K
    IDrugs; 2009 Jan; 12(1):5-6. PubMed ID: 19127494
    [No Abstract]   [Full Text] [Related]  

  • 26. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs.
    Al Hadidi S; Mims M; Miller-Chism CN; Kamble R
    Ann Intern Med; 2020 Aug; 173(4):320-322. PubMed ID: 32568574
    [No Abstract]   [Full Text] [Related]  

  • 27. Racial representation in clinical trials for dermatological new molecular entities.
    Ha MV; Wong C
    Clin Exp Dermatol; 2022 Feb; 47(2):386-388. PubMed ID: 34346107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. European Marketing Authorizations Granted Based on a Single Pivotal Clinical Trial: The Rule or the Exception?
    Morant AV; Vestergaard HT
    Clin Pharmacol Ther; 2018 Jul; 104(1):169-177. PubMed ID: 29023675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of Trials Associated With Drugs Approved by the Food and Drug Administration in 2015 and 2016.
    Eckert JC
    Med Care; 2020 Mar; 58(3):194-198. PubMed ID: 32106163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer Disparities and Black American Representation in Clinical Trials Leading to the Approval of Oral Chemotherapy Drugs in the United States Between 2009 and 2019.
    Ajewole VB; Akindele O; Abajue U; Ndulue O; Marshall JJ; Mossi YT
    JCO Oncol Pract; 2021 May; 17(5):e623-e628. PubMed ID: 33974825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Misreading race and genomics after BiDil.
    Kahn J
    Nat Genet; 2005 Jul; 37(7):655-6. PubMed ID: 15990879
    [No Abstract]   [Full Text] [Related]  

  • 32. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Ethnic drugs".
    Kahn J
    Hastings Cent Rep; 2005; 35(1):1 p following 48. PubMed ID: 15799501
    [No Abstract]   [Full Text] [Related]  

  • 34. Using race in clinical research to develop tailored medications. Is the FDA encouraging discrimination or eliminating traditional disparities in health care for African Americans?
    Ruel MD
    J Leg Med; 2006 Jun; 27(2):225-41. PubMed ID: 16728354
    [No Abstract]   [Full Text] [Related]  

  • 35. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept.
    Mogielnicki M; Swieczkowski D; Bachorski W; Zuk G; Gilis-Malinowska N; Zarzeka A; Merks P; Gruchala M; Jaguszewski M
    Cardiol J; 2016; 23(5):515-517. PubMed ID: 27723064
    [No Abstract]   [Full Text] [Related]  

  • 36. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The US Food and Drug Administration and Cardiovascular Medicine: Reflections and Observations.
    Califf RM
    Circulation; 2016 Aug; 134(7):501-3. PubMed ID: 27528644
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018.
    Wallach JD; Ramachandran R; Bruckner T; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133601. PubMed ID: 34751764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.